Can We Do a Better Job Preventing Clinically-Relevant Peripheral Neuropathy Resulting from Carboplatin/Paclitaxel Chemotherapy?: Cancer Investigation: Vol 22, No 3

Views

CrossRef citations to date

Altmetric

Abstract

Minor modifications in the standard “dose reduction” strategy commonly employed in the presence of developing carboplatin/paclitaxel-induced peripheral neuropathy may favorably impact the quality-of-life associated with use of this important combination chemotherapy regimen.

Keywords

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Can We Do a Better Job Preventing Clinically-Relevant Peripheral Neuropathy Resulting from Carboplatin/Paclitaxel Chemotherapy?

Information for

Open access

Opportunities

Help and information

Can We Do a Better Job Preventing Clinically-Relevant Peripheral Neuropathy Resulting from Carboplatin/Paclitaxel Chemotherapy?

Abstract

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature